Should I pile into this potential millionaire-maker share?

The directors of this well-financed firm reckon operations are moving along the path to commercialisation.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today’s full results for the 18 months to December from Creo Medical Group (LSE: CREO) told the story of a firm with lots of growth potential.

Operations are aimed at the medical device market and particularly the “emerging field” of surgical endoscopy. The directors asserted in the report that during the 18-month period, the firm made “considerable progress” developing its Speedboat device for use in Gastrointestinal (GI) therapeutic endoscopy, which is the first in a “suite of products” being developed for the CROMA Advanced Energy platform.

Still loss-making and revenue-free

It all sounded exciting and the directors reckoned operations have been moving along the path to commercialisation, but so far, the company has been losing money. Indeed, there was an underlying operating loss of £12.6m in the period, which compared to a loss of £5.6m for the prior 12-month period to June 2017.

As with all early-stage, loss-making enterprises, the big question is, will operations start to generate an income before the firm’s cash runs out? On that score, the news was positive. In August 2018, a placing of new shares raised £48.5m before expenses and has “substantially strengthened” the balance sheet with the firm reporting cash and cash equivalents of £44.6m at the end of the period, up from £13.7m in June 2017.

The directors now intend to accelerate physician training and the commercial rollout of the firm’s products “internationally” over the next few years. The race is on, but which will come first: meaningful operating cash inflow, or an empty bank account? There seems no doubt that the share remains speculative. If things click operationally and Creo Medical starts to generate decent revenues, shareholders could do well. But if the cash runs out before that happens, shareholders could suffer significant dilution or even total loss of their investment.

Optimistic outlook

Chief executive Craig Gulliford seemed optimistic in today’s report saying that the company has established a solid platform for future growth and the directors look forward “with confidence to another exciting year in 2019.”  However, he also owned up to not underestimating the challenge of changing the structures required to roll out the company’s system, or of gaining regulatory clearance for the other devices in the pipeline. But feedback from clinicians seeing the product in use has been positive.

However, I’d point out that, although Creo Medical’s Initial Public Offering was during December 2016 when it arrived on the stock market, the company was founded in 2003. So it’s been in the product development stage for a long time. Maybe we are indeed close to commercialisation. Chief financial officer Richard Rees believes so, saying in the report that the recent placing provided Creo Medical with the long-term platform to enable the further development of “multiple products through to commercialisation.”

Nevertheless, Creo Medical remains a jam-tomorrow proposition and carries high risks for investors. I’m looking for jam-today that comes with ongoing potential, so I’ll look elsewhere.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

This FTSE sell-off gives me an unmissable chance to buy cut-price UK stocks!

The last few months have been tough for UK stocks and their troubles aren't over yet, but Harvey Jones isn't…

Read more »

Investing Articles

Here’s the forecast for the Tesla share price as Trump’s policies take focus

The Tesla share price surged following Donald Trump’s election victory, but the stock is trading far above analysts’ targets. Dr…

Read more »

Investing Articles

£15,000 in cash? I’d pick growth stocks like these for life-changing passive income

Millions of us invest for passive income. Here, Dr James Fox explains his recipe for success by focusing on high-potential…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Here’s my plan for long-term passive income

On the lookout for passive income stocks to buy, Stephen Wright is turning to one of Warren Buffett’s most famous…

Read more »

artificial intelligence investing algorithms
Growth Shares

Are British stock market investors missing out on the tech revolution?

British stock market investors continue to pile into ‘old-economy’ stocks. Is this a mistake in today’s increasingly digital world?

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

My 2 best US growth stocks to buy in November

I’ve just bought two US growth companies on my best stocks to buy now list, and I think they’re still…

Read more »

Investing Articles

£2k in savings? Here’s how I’d invest that to target a passive income of £4,629 a year

Harvey Jones examines how investing a modest sum like £2,000 and leaving it to grow for years can generate an…

Read more »

Renewable energies concept collage
Investing Articles

Down 20%! A sinking dividend stock to buy for passive income?

This dividend stock is spending £50m buying back its own shares while they trade at a discount and also planning…

Read more »